Lisa Olson - Sep 16, 2021 Form 4 Insider Report for Magenta Therapeutics, Inc. (MGTA)

Role
Head of Research and Chief Scientific Officer
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for Lisa Olson
Stock symbol
MGTA
Transactions as of
Sep 16, 2021
Transactions value $
-$38,603
Form type
4
Date filed
9/20/2021, 05:00 PM
Previous filing
Sep 16, 2021
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGTA Common Stock Sale -$38.6K -5.74K -28.68% $6.73* 14.3K Sep 16, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents shares sold solely to pay taxes due upon the vesting of restricted stock units, as disclosed by the reporting person on the Form 4 filed on September 16, 2021.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.87, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Head of Research and Chief Scientific Officer